Tiefenbacher Pharmaceuticals successfully launches generic versions of Abiraterone and value-added product Abiraterone/Prednisolone, Prostate Cancer

We at TIEFEENBACHER PHARMACEUTICALS aim to improve peoples´ lives around the world by making medicines better affordable, better available, and better than before! That´s why we are excited to share that we have successfully prepared the launch of the generic versions of Abiraterone and the value-added product of Abiraterone/Prednisolone for a market entry in Europe.

For the mono product Abiraterone, we were able to achieve a day one launch after patent expiration, making this important therapy finally more affordable for patients around the world. With the combination product Abiraterone/Prednisolone we offer a value-added product which comes in a special combi blister packaging improving patients´ compliance, physicians´ convenience, and protecting the environment.

Abiraterone and the combination product Abiraterone/Prednisolone are used to treat men with prostate cancer. The 500 mg (mono product) and 500 mg + 5 mg (combination product) tablets will be marketed in Europe by our partners. A launch in further international markets will follow soon.

TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes affordable high-quality healthcare solutions as well as medical devices worldwide. We provide over 180+ pharmaceuticals products across various therapeutic categories in 40+ dosage forms. With our in-house product development, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines including high-potent for global markets. 
For more information about our finished dosage forms including highly potent drugs and e-healthcare solutions, please contact Tiefenbacher Pharmaceuticals info@tiefenbacher.com or visit us on www.tiefenbacher-pharmaceuticals.com